SightLife Surgical Rebrands as CorneaGen, Offers New Products

April 13, 2018: By Jon Swedien

SightLife Surgical announced April 12 that it has changed its name to CorneaGen.

The Seattle-based subsidiary of the nonprofit SightLife also announced it has three new product offerings:

–Tissue storage media with antifungal amphotericin B (Ampho B), which is used to combat rising rates of post-transplant fungal infections;

–The Geuder Preloaded Glass Cannula for Descemet’s membrane endothelial keratoplasty (DMEK);

–Intacs corneal implants for keratoconus.

The company in the past 18 months has begun offering more products and services aimed at transforming how corneal surgeons treat the cornea, President and CEO Monty Montoya said. The company decided to change its name to reflect its focus, Montoya said.

In March, the company also acquired the KAMRA corneal inlay from AcuFocus.

Regarding Ampho B, CorneaGen said surgeons across the US have long requested it. CorneaGen is now the first US company to offer storage media with Ampho B, the company said.

The Geuder Preloaded Glass Cannula for DMEK is the first specifically designed for preloaded cornea tissue, CorneaGen said. The device uses a locking system that minimizes damage to the tissue during transport, CorneaGen said.

Intacs corneal implants are designed to reduce or eliminate myopia and astigmatism in keratoconus patients, CorneaGen said. Intacs corneal implants help restore functional vision and potentially defer the need for a corneal transplant. CorneaGen said it has signed an exclusive US distribution agreement for Intacs with Addition Technology, an AJL Ophthalmics subsidiary.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023